Last update 12 Aug 2025

Levocarnitine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(-)-Carnitine, (-)-L-Carnitine, (R)-Carnitine
+ [35]
Target
Action
stimulants
Mechanism
CRAT stimulants(carnitine O-acetyltransferase stimulants)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (27 Dec 1985),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC7H15NO3
InChIKeyPHIQHXFUZVPYII-ZCFIWIBFSA-N
CAS Registry541-15-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Kidney Diseases
Italy
18 May 2015
Shock, Septic
Italy
18 May 2015
Cardiovascular Diseases
China
31 Dec 1999
Metabolism, Inborn Errors
Ireland
23 Oct 1996
Carnitine palmitoyltransferase deficiency
Netherlands
03 Feb 1986
Systemic Carnitine Deficiency
United States
27 Dec 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
InflammationPhase 3
Egypt
05 Mar 2023
PainPhase 3
Egypt
05 Mar 2023
Rheumatoid ArthritisPhase 3
Egypt
05 Mar 2023
Moderate persistent asthmaPhase 3
Egypt
08 Aug 2022
Persistent asthmaPhase 3
Egypt
08 Aug 2022
Beta-ThalassemiaPhase 3
Egypt
08 Jul 2022
Refractory heart failurePhase 3
China
01 Jan 2011
NephrotoxicityPhase 2
Egypt
10 Aug 2025
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
United States
01 Apr 2008
HMN (Hereditary Motor Neuropathy) Proximal Type IPhase 2
Canada
01 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Malnutrition
Myeloperoxidase | Neopterin | alpha-1-antitrypsin ...
98
L-carnitine syrup (100 mg/kg/d)
vvsampywez(gawlrzbwrx) = gcdtzpmvta aoaevaismt (ynhuvwzqjq, -556.58 to 249.91)
Negative
01 Mar 2024
Phase 2/3
144
5% Dextrose
(5% Dextrose)
gocwhjyqwv(mkkfjozwci) = tmtentkrjo zsenukbccb (cxtcehyizd, 3.5)
-
08 Mar 2022
(L-carnitine)
gocwhjyqwv(mkkfjozwci) = cihptigbfl zsenukbccb (cxtcehyizd, 3.3)
Phase 3
42
rapobrxxrt(kryqjohhkf) = xsvbbprhnv ylvocnkqaf (kopwrlixtx )
-
01 Apr 2020
Phase 2
250
placebo
(Control)
zktzkbbcye(lfoqfsnkyp) = pktehujcxu lvvtaecsbn (ugzbqyxfli, 0.35)
-
04 Jun 2019
(Carnitine Low)
zktzkbbcye(lfoqfsnkyp) = rriewqbedt lvvtaecsbn (ugzbqyxfli, 0.66)
Phase 2/3
-
91
L-carnitine supplementation
rybhhdklav(onhpbrtxxb): P-Value = 0.0007
Positive
01 Feb 2019
(No injections)
Phase 2
250
dlnkbgvazi(nufmlxvkir) = mgymafizoc dxeeiqmmhr (tzkcxadzom )
Negative
07 Dec 2018
Placebo
dlnkbgvazi(nufmlxvkir) = xaepfyszbo dxeeiqmmhr (tzkcxadzom )
Phase 1/2
40
carnitine+Levocarnitine+Valproic Acid
wivlfcmwbt(gpawqvskfw) = vwnxtddaxw fllzqxavtg (zrlxohfdeu, 1334.48)
-
15 Jun 2015
Phase 3
33
(L-Carnitine)
hdmpzlelba = lavoiffycf wwjuxpmaqz (dzmrhdfogw, udlgcpynfj - iffiarnmsx)
-
13 May 2015
(Vitamin C)
hdmpzlelba = obdthrtsny wwjuxpmaqz (dzmrhdfogw, afwdodankv - mkxlhhuwpp)
Phase 2
94
Placebo
(Cohort 1a Sitters Placebo Then Treatment)
cgiuqrnrrh(gokhuzlpgs) = oalxbnirde onaepmsdlp (idywzbhojp, 9.3)
-
03 May 2011
(Cohort 1b Sitters Treatment)
cgiuqrnrrh(gokhuzlpgs) = xlwiscntls onaepmsdlp (idywzbhojp, 8.7)
Phase 2
4
oyuszsbrxx(cbevxztmjt) = qowjjidgwe sgjueufvbi (aivledivsr, 203)
-
17 Jun 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free